Annovis Bio, Inc. (ANVS) Materially Misrepresented the Outcome of its ANVS401 Clinical Trials
According to a class action complaint filed on behalf of Annovis Bio, Inc. shareholders, between May 21, 2021 and July 28, 2021, Annovis conducted two Phase 2a clinical studies for its lead compound, ANVS401. One trial, conducted in collaboration with the Alzheimer’s Disease Cooperative Study, examines 24 early Alzheimer’s disease patients. The second trial examines both Alzheimer’s (14) and Parkinson’s patients (54). On May 21, 2021, Annovis touted the positive results of its ANVS401 clinical trials, noting improvements in the ANVS401-treated group compared to placebo group. Further, the Company stated, “Patients treated with ANVS401 for 25 days showed statistically significant cognitive improvement as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11.” The positive statements caused the Company’s stock to skyrocket from $26.40 per share on May 20, 2021, to $60 per share on May 21, 2021.
On July 28, 2021, Annovis reported interim clinical data from its Phase 2a trial. Contrary to what it had previously reported, the Company revealed that Alzheimer’s patients 25 days after treatment failed to show statistically significant improvement compared to the placebo. Annovis also reported that, although patients showed cognitive improvements in certain areas, the results were not statistically significant. On this news, the Company’s share price fell $65.94, or 60%, to close at $43.50 per share on July 29, 2021, and has continued to decline
If you purchased shares of Annovis Bios, Inc. (ANVS) securities between May 21, 2021 and July 28, 2021, you have until October 18, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.